Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 6/20 | 0.34 |
| ▸ | HTR7 | P34969 | 6/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396586 | 0.89 | DPP4 (0.49) | ALDH1A1DPP4LMNAHTR1AHTR7 | |
| SCHEMBL670375 | 0.89 | DPP4 (0.49) | ALDH1A1DPP4LMNAHTR1AHTR7 | |
| SCHEMBL1239264 | 0.89 | DPP4 (0.49) | ALDH1A1DPP4LMNAHTR1AHTR7 | |
| SCHEMBL22481429 | 0.87 | DPP4 (0.45) | DPP4HTR1AHTR7 | |
| SCHEMBL5702040 | 0.82 | ACE (0.47) | ALDH1A1LMNA | |
| SCHEMBL5702012 | 0.82 | ACE (0.47) | ALDH1A1LMNA | |
| SCHEMBL29098712 | 0.76 | SMN1; SMN2 (0.34) | DPP4SMN1; SMN2 | |
| SCHEMBL2770377 | 0.76 | FKBP1A (0.42) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1074843 | 0.74 | DPP4 (0.33) | DPP4SMN1; SMN2 | |
| SCHEMBL1074840 | 0.74 | DPP4 (0.33) | DPP4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465891-A4 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARM INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | GUILFORD PHARMACEUTICALS | 2005-03-31 | — | — | US | disclosed |
| EP-1465891-A2 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003057666-A2 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003057144-A2 | CHANGE INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | DPP4, DPP3, DPP7 | ALDH1A1 1387/4885DPP4 1/4885LMNA 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.